The acne treatment market is expected to grow, at a CAGR of 5.9% between 2021-2031 . Digital health is taking a prominent position in our lives, making it an important tool in future medical device trends. This would be the general perspective of the healthcare vertical in the forecast period.
According to the latest revised industry analysis by Persistence Market Research, the global acne treatment market was valued at over US$5.8 billion in 2020, and is expected to show a CAGR of close to 6% over the forecast period (2021 -2031)
In the United States, acne affects approximately 50 million people a year. The increasing rate of skin diseases is one of the main factors driving the growth of the market globally. Acne is most commonly seen among teenagers, but it can also be seen in people of all ages.
According to the American Academy of Dermatology Association, more than 85% of the population between the ages of 12 and 24 have suffered from acne minor at least once or twice, and this can continue into people in their 30s and 40s years
Get A Free Sample Of Acne Treatment Market @ https://www.persistencemarketresearch.com/samples/5279
The significant prevalence of acne has led to an increased awareness of considering skin treatment. This, in turn, is expected to drive demand for acne treatment products. As new drugs and treatments are required to replace older methods such as antibiotics, acne research and development creates avenues and opportunities for market players. As a result, various industry players are receiving approvals from regulatory authorities.
Some of the recent approvals include AKLIEF (trifarotene) 0.005% cream (Oct 2019, Galderma SA), ARAZLO (tazarotene) Lotion, 0.045% (Bausch Health Companies Inc., Dec 2019), and ACZONE (DAPSONE) GEL (September 2019). 2019, Almirall SA). Therefore, the increase in approvals supports a positive outlook for continued healthy growth of the market.
Company Profile:
- Galderma SA
- lumenis ltd
- Alma Lasers, Sisram Medical Company
- cutera inc.
- Almirall, SA
- johnson & johnson services inc.
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd.
- Stiefel Laboratories, a GSK company
- medical candle
Switch to the “Methodology” tab @ https://www.persistencemarketresearch.com/methodology/5279
Key takeaways from the market study
- By treatment, retinoid therapy holds about 40% of the market value globally, primarily due to its effectiveness in controlling the spread of acne compared to other products and in reducing acne scar formation.
- Based on the route of administration, the topical route of administration is the leader with more than 60% of the market share. The ease of application and increased availability of lotions, creams and gels are positively driving demand for topical products.
- Inflammatory acne is estimated to dominate the market by type. This segment represented approximately 53% of market share. The significant scarring and pain associated with this type of acne is a key factor driving the segment.
- Institutional sales dominate acne treatment with a 52% market share. The increasing number of dermatology clinics and the growing preference for in-office acne treatment procedures to achieve faster results have created a positive impact on the growth of the market.
- By region, North America will dominate the global acne treatment market with a value share of around 44%.
Europe is slated to be the second largest leading region with a 20% value share during the forecast period.
“The rising prevalence of acne, the preference for the use of combination treatments, and new product launches and approvals are expected to drive market growth in the coming years,” says an analyst at Persistence Market Research.
Purchase this report @ https://www.persistencemarketresearch.com/checkout/5279
market competition
New product launches and approvals, agreements, collaborations and partnerships have become the key growth strategy adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.
- In January 2021, Eligo Biosciences SA and GlaxoSmithKline PLC entered into a research collaboration to develop gene therapies to treat or prevent the growth of normal acne.
- In February 2020, Almirall SA signed a license agreement with Paratek Pharmaceuticals, Inc. to expand Almirall’s Seysara in the Chinese market.
What does the report cover?
Persistence Market Research offers a unique perspective and actionable information on the Acne Treatment market in its latest study, which presents a historical assessment of demand from 2016 to 2020 and projections for 2021 to 2031.
The research study is based on product (therapeutic treatment [antibiotics, retinoid therapy, hormonal drugs, anti-inflammatory drugs, and chemical peels] and devices [laser devices and radiofrequency therapy]), route of administration (topical and oral), type of acne (inflammatory and non-inflammatory acne), distribution channel (institutional sales [hospitals and specialty clinics] and retail sales [retail pharmacies, drugstores and online sales]), in seven key regions of the world.
About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com